Viking Therapeutics (NASDAQ: VKTX) and HCA Healthcare (NYSE: HCA) are emerging as potential high-value stocks in the currently underperforming healthcare sector. Viking, a clinical-stage biotech, is nearing the completion of its phase 3 trial for VK2735, a weight-loss drug that analysts believe could outperform existing treatments like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. With bullish price targets reaching as high as $125 per share, Viking’s promising pipeline could attract significant investor interest as the readout approaches.
HCA Healthcare, the largest operator of healthcare systems in the U.S., is also positioned for growth, driven by an aging population that requires increased medical care. The company reported a 7% revenue increase in the last quarter and anticipates further growth, bolstered by its innovative use of AI to optimize operations. While some analysts project substantial price increases, HCA is viewed as a more stable long-term investment.
Investors should consider both stocks as part of a diversified strategy in the healthcare sector, particularly given the potential for Viking’s breakthrough drug and HCA’s robust fundamentals amidst demographic shifts.
Source: nasdaq.com